Insider Transactions in Q1 2021 at Alaunos Therapeutics, Inc. (TCRT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2021
|
Christopher Bowden Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+50.0%
|
-
|
|
Mar 04
2021
|
J Kevin Buchi Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+50.0%
|
-
|
|
Mar 04
2021
|
James Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+50.0%
|
-
|
|
Mar 04
2021
|
Robert W Postma |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+0.21%
|
-
|
|
Mar 04
2021
|
Mary Thistle Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Mar 04
2021
|
Jaime Vieser |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+0.68%
|
-
|
|
Mar 04
2021
|
Holger Weis |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+5.61%
|
-
|
|
Mar 04
2021
|
Eleanor De Groot EVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
50,825
+16.5%
|
-
|
|
Mar 04
2021
|
Heidi Hagen Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+42.43%
|
-
|
|
Mar 04
2021
|
Robert Hadfield Chief Legal Officer and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
43,500
+19.74%
|
-
|
|
Mar 04
2021
|
Jill Buck EVP, GM Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+12.0%
|
-
|
|
Jan 08
2021
|
Robert Hadfield Chief Legal Officer and Sec. |
SELL
Open market or private sale
|
Direct |
26,500
-16.58%
|
$79,500
$3.12 P/Share
|
|
Jan 08
2021
|
Kevin G Lafond SVP, Treasurer & CAO |
SELL
Open market or private sale
|
Direct |
18,020
-21.98%
|
$54,060
$3.09 P/Share
|
|
Jan 08
2021
|
Jill Buck EVP, GM Gene Therapy |
SELL
Open market or private sale
|
Direct |
27,894
-12.27%
|
$83,682
$3.12 P/Share
|
|
Jan 04
2021
|
Laurence James Neil Cooper President and CEO |
SELL
Open market or private sale
|
Direct |
105,693
-5.55%
|
$211,386
$2.71 P/Share
|
|
Jan 04
2021
|
Eleanor De Groot EVP, Operations |
SELL
Open market or private sale
|
Direct |
21,620
-9.48%
|
$43,240
$2.72 P/Share
|